Switzerland / 5 Trends in Swiss Biotech
While the Swiss biotech sector is inevitably facing many of the same funding challenges as the global industry and is still struggling to make a meaningful comeback from its 2022…
Interpharma is the association of research-based pharmaceutical companies in Switzerland. It was founded in 1933 in Basel, Switzerland. Member firms are Novartis, Roche, Merck Serono, Actelion, Amgen Switzerland AG, Bayer Schering Pharma Schweiz, Cilag Switzerland, Vifor Pharma. In 2010, the Interpharma members spent 25 billion Swiss Francs on research an development which makes up 21 percent of their total sales in pharmaceuticals.
Interpharma is committed to creating conditions conducive to innovation in both Switzerland and abroad so as to promote pharmaceutical research, development and production. It supports all efforts to create a social, economic and political environment that strengthens Switzerland as a center of pharmaceutical research and production. Therefore, the association is an active partner in national health policy and fosters dialogue through its analyses, studies and other publications and events. Interpharma promotes a greater public understanding of new technologies and methods used in biomedical research and fosters the rigorous protection of intellectual property as an essential precondition for successful pharmaceutical research at the global and national level. It wants to help giving patients access to the latest medical advances as well as to safeguard and promote the development of professional and ethical standards in the research, development and marketing of pharmaceuticals.
Contact
Interpharma, Petersgraben 35
While the Swiss biotech sector is inevitably facing many of the same funding challenges as the global industry and is still struggling to make a meaningful comeback from its 2022…
The biggest pharma news from Switzerland, including the industry’s cautious reaction to a new free trade deal with India; the drop in Roche’s share prices; Novartis’ acquisiton of MorphoSys, and…
For the Swiss Agency for Therapeutic Products (Swissmedic), one of the world’s leading regulatory authorities, 2023 was an important year. Not only did the agency gain recognition from the World…
Obesity is pharma’s new El Dorado. Following the spectacular market success and sky-high sales projections of next-generation obesity treatments, many actors – both large and small – are looking to…
2023 was a tumultuous year for the pharma industry, with much wailing and gnashing of teeth from executives over the Inflation Reduction Act in the US as well as updated…
As former parent company Novartis centres its efforts on its “pure-play” innovative medicines business, Sandoz is increasingly betting on biosimilars. Having already launched a version of AbbVie’s blockbuster arthritis treatment…
At this year’s Swiss Biotech Day, the Swiss Biotech Association celebrated its 25 years of existence and proved the ability of the sector to weather geopolitical disruptions and funding challenges…
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to, and facilitate the development of, life-saving medicines for low- and middle-income countries. Executive…
The latest news from Swiss pharma and healthcare, including the startling announcement that Switzerland is set to destroy a full nine million doses of expired Moderna COVID-19 vaccines, with over…
Roche slipped from second to fifth place in this year’s ranking of the world’s top pharmaceutical companies, reported uninspiring numbers for the first half of the year and seen its…
After a Moderna-Lonza production site and a Merck manufacturing facility were set up in western Switzerland, the country continues to attract big pharma capital with a CHF 200 million investment…
Lonza’s global head of Mammalian Biologics, Jennifer Cannon, talks about disruption in the CDMO industry, explains how the Swiss giant is reimagining new models based on risk-sharing, and goes through…
See our Cookie Privacy Policy Here
